Trial Profile
A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Remetinostat (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors TetraLogic Pharmaceuticals
- 18 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 18 Oct 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2017.
- 18 Oct 2016 Planned initiation date changed from 1 Feb 2016 to 1 Feb 2017.